The world is currently faced with a pandemic of novel coronavirus disease 2019 (COVID-19), which is caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Join our upcoming webinar to learn how to manage ongoing CAGT trials, get an overview of the epidemiology, pathophysiology, and clinical manifestations of COVID-19, the application of cell and gene therapies (CAGT) to this disease, new CAGT for COVID-19 on the horizon, and key considerations for CAGT trials. Hear lessons learned conducting CAGT trials during the early period of the COVID-19 crisis that may help in planning for the future.
Key take-aways:
- Understand epidemiology, basic science, pathophysiology, and clinical manifestations of infection with SARS-CoV-2
- Discover potential application of CAGT therapies for treatment of COVID-19
- Get an overview of new CAGT COVID-19 therapies in development (cell therapy for ARDS) and application of CAGT science to COVID-19 (CRISPR for treatment)
- Considerations for COVID-19 and CAGT trial
- Study design – placebo-controlled, endpoints
- How to manage trials and overcome operational issues – administration, streamlining ops, virtual follow up
- Study population and ethical issues – critically ill, consent, placebo-controlled, burden on sites during crisis
Click here for additional information and registration details.
Related Content
Evidence Matters 2022
Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.
Achieving Consensus When Everyone is an Expert, but No One Agrees
Join experts from PHAR, Novartis, and Bausch Health for a discussion around the Delphi panels and how the results are used.
Accelerating the Generation of Payer Insights and Evidence Across the Product Lifecycle to Achieve Optimal Access
Experts will present opportunities for using agile platforms and fit-for-purpose engagement models that can drive an iterative approach to obtaining payer insights and developing impactful evidence generation strategies.